The meeting is part of the SPARK Norway Educational Forum Series 2: Quality, regulatory and IP – monthly open meetings organized by UiO:Life Science and SPARK Norway partners.
Sign up by filling out the form at the bottom of this web page.
Programme
Two highly experienced life science professionals will share their thoughts on how to work with a TPP in order to create a successful product in two different markets, which requires different strategies:
- Vaccines do not always have a high commercial value in the market, but have a high value from a public health point of view
- Traditional pharmaceutical drugs have a very high commercial value in the market
Gunnstein Norheim
Director Vaccine Science team at CEPI
Gunnstein has extensive experience with infectious diseases and vaccine research. Since 2014 he has been involved in the coordination, planning and implementation of the phase III clinical trial with a novel vaccine against Ebola in Guinea, and he is a member of its Study Steering Group.
He has been in the CEPI Secretariat since its inception in early 2016, serving as a member of the CEPI SAC since October 2016 and as Director for Vaccine Science team at CEPI since January 2018.
Steinar Ø. Thoresen
Medical Director at AbbVie
Steinar has a long carrier from both academic research and pharmaceutical industry. He is a medical doctor specialized in pathology and epidemiology with a PhD in breast cancer. For 15 years he was the director of the national cancer screening program and he held a professorship at University of Bergen for more than 20 years. From 2009 he was Medical Director in GSK, and since 2013 he has been Medical Director in AbbVie.
Q&A